RaySearch Laboratories publ : and Mevion announce strategic partnership

RaySearch and Mevion to develop advanced treatment planning solutions for the Mevion S250 with HYPERSCAN. Collaboration to benefit from RayStation's advanced planning capabilities and HYPERSCAN's fast pencil beam scanning proton therapy technology

RaySearch Laboratories AB and Mevion Medical Systems, Inc., two companies that are leading the field of proton therapy, are announcing a partnership to develop advanced treatment planning solutions for the MEVION S250 proton therapy platform. RaySearch's RayStation® treatment planning system supports the MEVION S250's current configuration so this new partnership will focus on validating the use of the RayStation® treatment planning system for Mevion's new HYPERSCAN pencil beam scanning technology, and developing advanced planning solutions that take advantage of HYPERSCAN's rapid pencil beam delivery capabilities.

"Mevion and RaySearch are leaders in the proton therapy marketplace and it is only natural that we would collaborate," said Joseph K. Jachinowski, President and CEO of Mevion Medical Systems. "By partnering, we are creating a synergy that allows clinicians to maximize the benefits of our technologies and realize the full potential of HYPERSCAN's fast pencil beam scanning delivery."

Johan Löf, President and CEO of RaySearch Laboratories AB said: "We are excited to collaborate with Mevion to combine the powerful treatment planning tools in RayStation with the HYPERSCAN technology. Together we will help deliver advanced cancer care to the patients who need it most."

The partnership is being announced at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO), held September 14 - 16 in San Francisco. More information is available at the Mevion booth 728 and the RaySearch booth 2315

About HYPERSCAN
HYPERSCAN's patented technology, paired with the direct and efficient proton beam generation of the MEVION S250 platform, allows tumor volumes to be quickly scanned in a matter of seconds. This speed makes HYPERSCAN's treatment delivery much less sensitive to patient and tumor motion.

HYPERSCAN has not been cleared by the USFDA for clinical use. 

About Mevion Medical Systems
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion's flagship product, the MEVION S250 proton therapy platform, is the only modular, single room proton therapy system currently on the market. The MEVION S250 integrates with standard radiation therapy workflow and provides a proton therapy treatment environment at a fraction of the cost, footprint and operational complexity of conventional systems.

Mevion is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan. For more information, please visit www.mevion.com.

About RayStation®
RayStation® integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch provides the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch's products are distributed through licensing agreements with leading partners such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched via partners and RaySearch's software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: [phone]
[e-mail]

Provision Center for Proton Therapy treats first patients in Tennessee with the RayStation® treatment planning system from RaySearch Laboratories AB.

On May 27, 2014 the first patient was treated with the Pencil Beam Scanning (PBS) treatment technique at the Provision Center for Proton Therapy in Knoxville, Tennessee, the state's first and only proton therapy treatment facility. The clinical patient treatment plans were created entirely on RayStation®, RaySearch's highly advanced treatment planning and dose tracking software platform and delivered on the IBA proton system.

PBS is the most sophisticated delivery technique in proton therapy. It enables Intensity Modulated Proton Therapy (IMPT) that allows clinicians to target a cancerous tumor by controlling both the intensity and the spatial distribution with millimeter precision. Earlier this year, the first patients were treated using the Uniform Scanning technique at Provision.

The proton center opened less than two years after breaking ground in April 2012. A 220-ton cyclotron, a particle accelerator that produces protons, was installed a year ago in January 2013 at the center, which sits on the 120-acre comprehensive outpatient medical campus at Dowell Springs in Knoxville. In close collaboration with RaySearch, Provision was able to get the treatment planning network installed, have data collected and modeled, perform extensive quality assurance and train their entire staff in only four months. "We knew this was an aggressive timeline, but we were very confident in the technologies that we had selected, and also in the people that were focused on the project. Providing this region with proton therapy as an option for cancer treatment is a vision that our organization has tirelessly pursued. We are pleased with results and happy with our selection of RaySearch as our partner," said Niek Schreuder, the VP and Chief of Medical Physics for the center.

"The Provision Center for Proton Therapy is a model for what can be achieved when people from multiple organizations come together and work towards a common goal. Niek and his team brought a lot of knowledge and expertise to the table and implemented a cutting edge program safely and efficiently," says Marc Mlyn, President of RaySearch Americas, Inc. "We are pleased that this was the first site in the USA that implemented RayStation® clinically for proton therapy - both for Uniform Scanning and PBS."

"Provision has a culture for excellent patient care and takes pride in being at the forefront of leading-edge technologies," said Marcio Fagundes, M.D., board-certified radiation oncologist and Medical Director at the Provision Center for Proton Therapy. "The Provision Center for Proton Therapy is an example of such commitment. Provision selected RayStation® with the expectation that it would improve efficiency and provide excellence in patient planning. RayStation® has not only achieved these expectations but has changed the landscape of all planning environments currently in practice."

"Proton therapy is a prioritized area for us and we have worked very hard to create the leading solution for proton treatment planning with support for all treatment modalities. It is of course a historical event for us that RayStation® has now been implemented clinically for proton therapy using the PBS treatment technique meaning that the system is used to create the most advanced cancer radiation treatments available", says Johan Löf, CEO of RaySearch.

The current version of RayStation® that has FDA clearance supports all relevant proton treatment techniques such as Uniform Scanning, Double Scattering and PBS / IMPT.

About Provision Center for Proton Therapy
Provision Center for Proton Therapy is the first cancer treatment center of its kind in Tennessee and only the second in the Southeastern United States. Open to all credentialed physicians and health systems in the region, the Provision Center for Proton Therapy will have three treatment rooms and will be able to treat up to 900 cancer patients annually, and will bring in many patients from outside the area. Treatments will typically require daily 30 - 45 minute sessions for two months. The next closest location offering proton therapy is 350 miles away. The center brings to Knoxville an advanced cancer treatment capability that presently is available in only a handful of cities. It is one of only 14 in the nation and 46 in the world.

About RayStation®
RayStation® integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch provides the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch's products are distributed through licensing agreements with leading partners such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched via partners and RaySearch's software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: [phone]
[e-mail]

Download

At the Annual General Meeting of RaySearch Laboratories AB (publ) held on 27 May, 2014, the following resolutions were adopted:

It was resolved that no dividends be paid out to the shareholders since the company is in a phase of rapid expansion that requires capital. The accumulated profit of SEK 29,461,000 was brought forward and balanced in the new accounts.

It was resolved to approve discharge from personal liability for the members of the Board and the President.

It was resolved to adopt the guidelines for remuneration to senior executives proposed by the Board, to apply until the close of the Annual General Meeting 2015.

It was resolved that remuneration to Board members who do not receive a salary from any Group company, total SEK 760,000 for the period extending to the close of the next Annual General Meeting, of which SEK 440,000 will be paid to the Chairman and SEK 160,000 to each of the Board members elected by the Annual General Meeting, who does not receive a salary from any Group company.

It was resolved that the Auditors' fees be paid in accordance with current approved invoicing.

It was resolved to re-elect Carl Filip Bergendal, Erik Hedlund, Johan Löf and Hans Wigzell as Board members of the company and to re-elect Erik Hedlund as Chairman of the Board

It was resolved to re-elect the auditing firm Ernst & Young as auditors, with authorized public accountant Per Hedström as auditor in charge.

It was resolved to authorize the Board to resolve on new issues of Series B shares, on one or several occasions up until the Annual General Meeting of 2015, in accordance with the proposal by the Board.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch provides the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch's products are distributed through licensing agreements with leading partners such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched via partners and RaySearch's software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: [phone]
[e-mail]

Download

In December 2013 an extended version of RaySearch's RayStation® 4.0 treatment planning system was CE-marked and released for clinical use to multiple markets. The new version contained tools for optimization of proton treatments using the pencil beam scanning technique (PBS). RaySearch has now received 510(k) clearance for this new version, which means that this new functionality can be sold and marketed in the US.

Proton therapy is considered the most advanced form of radiation therapy due to its superior dose distribution and fewer side effects. Protons deposit the majority of their energy within a precisely controlled range, thus making it easier to target the tumor and to spare healthy surrounding tissue. PBS is the most sophisticated technique to deliver proton therapy. It enables Intensity Modulated Proton Therapy (IMPT) that allows clinicians to target a cancerous tumor by controlling both the intensity and the spatial distribution with millimeter precision.

The proton module in RayStation® contains all the state-of-the-art tools needed for PBS such as multiple field optimization, single field uniform dose and distal edge tracking techniques.

"We have won several orders and been the most successful supplier of solutions for proton treatment planning over the last year. Our position on the US market becomes even stronger now that we have market clearance for all relevant techniques for proton therapy", says Johan Löf, CEO of RaySearch.

About RayStation®
RayStation® integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch provides the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch's products are distributed through licensing agreements with leading partners such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched via partners and RaySearch's software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: [phone]
[e-mail]

Download

RaySearch Laboratories AB (publ) announces that the first clinical mARC treatment, planned with RaySearch's treatment planning system RayStation®, has been delivered at Europe Hospitals in Brussels, Belgium. mARC (Modulated Arc) is a type of rotational IMRT treatment carried out with Siemens Artiste® linear accelerators, where the beam is kept turned on as the gantry rotates around the patient. The concept enables as high treatment precision as with ordinary IMRT but with significantly faster delivery times.

Europe Hospitals is the largest private hospital group in Brussels with 716 stay-in beds and 200 one-day beds. They employ about 300 medical doctors and 2,000 staff members spread over two sites. Brussels Europe Hospitals run a private Radiotherapy and Oncology Department. The External Beam Radiotherapy department is fully equipped for modern external beam and HDR-brachytherapy treatments.

"We acquired RayStation® in 2013 based on the breadth of technology including support of rotational IMRT for all types of linear accelerators, the high speed of planning and dose computation, the robustness of optimization and the ease of analysis. Now we have implemented mARC or rotational IMRT on the Siemens Artiste® linear accelerators clinically, and on April 17 the first patient worldwide received an mARC treatment that was planned in RayStation®", says Dr. Carl Salembier, Head of the Radiation Oncology department at Brussels Europe Hospitals.

Alex Rijnders, Chief Medical Physicist at Brussels Europe Hospitals, adds: "We are happy that we can offer our patients this advanced treatment modality. Thanks to the powerful capabilities of RayStation®, treatment planning turned out easy and efficient, leading to optimal solutions and high plan quality. We are looking forward to further collaboration with RaySearch in exploring the possibilities offered by the mARC treatment modality, such as hybrid treatments."

Johan Löf, CEO of RaySearch, comments: "The unique optimization algorithms in RayStation® enabling rotational therapy with Siemens Artiste® linacs were developed together with Siemens in 2012. As they have now been validated clinically, I believe RayStation® is the only modern treatment planning system that offers adequate support for all advanced treatment modalities from all the major hardware vendors including Siemens. This capability makes RayStation® a highly attractive alternative for clinics with Siemens linear accelerators or a mix of linear accelerators from different vendors."

About RayStation®
RayStation® integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch's products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched through partners and RaySearch's software is used at 2,500 clinics in more than 65 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: [phone]
[e-mail]

Download

As of today, the 2013 Annual Report of RaySearch Laboratories AB (publ) is available in Swedish as a pdf file on the company's website www.raysearchlabs.com. The printed version in Swedish is expected to be distributed to the shareholders around May 12. The English version is under production and will be finalized in conjunction with RaySearch's Annual General Meeting on Wednesday, May 27, 2014. Printed annual reports can be ordered from the company, telephone [phone].

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch's products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched through partners and RaySearch's software is used at 2,500 clinics in more than 65 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Anders Martin-Löf, CFO, RaySearch Laboratories AB
Telephone: [phone]
[e-mail]

Download

The shareholders in RaySearch Laboratories AB (publ), corporate identity no. 556322-6157, are hereby invited to the Annual General Meeting Tuesday 27 May, 2014, at 6:00 p.m., in Grünewaldsalen, Konserthuset, Stockholm, Sweden.

RIGHT TO PARTICIPATE AND NOTICE

Shareholders who wish to participate in the Annual General Meeting and to have the right to vote, must:

-     be recorded in the share register maintained by Euroclear Sweden AB (Euroclear) not later than Wednesday, 21 May, 2014,

-     notify the company of their intention to participate in the Annual General Meeting not later than Wednesday, 21 May, 2014, at 4:00 p.m. by mail to RaySearch Laboratories AB (publ), Sveavägen 25, SE-111 34 Stockholm, Sweden; by telephone [phone]; by fax [phone]; or by e-mail to [e-mail]. Assistants may accompany shareholders to the Meeting only if the shareholder has provided notice of the number of assistants, a maximum of two, in the manner described above for notification of participation. Notification should include the shareholder's name, personal or corporate identity number, shareholding, address and telephone number.

Shareholders who have trustee-registered shares through a bank or broker, must request to temporarily register the shares in their own name with Euroclear to be entitled to exercise their voting rights at the Meeting. Such shareholders must inform the trustee of this request in adequate time prior to Wednesday, 21 May, 2014, when such registration must have been completed.

POWER OF ATTORNEY FORM
If shareholders intend to be represented by proxy, the shareholder must issue a written power of attorney, duly dated and signed. For practical reasons, the power of attorney should be submitted to the company in advance. Please note that the original of any power of attorney must be presented and that it cannot therefore be sent by fax or internet. A power of attorney form is available on the company's website www.raysearchlabs.com and will be sent at no cost to shareholders who request it and provide their postal address or email address. A power of attorney is valid no longer than one year from its issuance, unless a longer period of validity is expressly stated; however, in no event longer than five years. Representatives of legal entities must present a copy of a registration certificate or corresponding authorization document that indicates the authorized signatory.

PROPOSED AGENDA

1.    Opening of the Meeting.
2.    Election of a Chairman of the Meeting.
3.    Preparation and approval of the list of shareholders entitled to vote at the Meeting.
4.    Election of one or two minute-checkers.
5.    Approval of the proposed agenda.
6.    Determination whether the Meeting has been duly convened.
7.    Address by the CEO.
8.    Presentation of the Annual Report and the Auditors' Report as well as the consolidated financial statements and the Auditors' Report for the consolidated financial statements for the 2013 fiscal year.
9.    Resolutions concerning
      (a)  the adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet;
      (b)  the disposition to be made of the company's profits or losses as shown in the balance sheet adopted by the Meeting; and
      (c)  the discharge of the members of the Board of Directors and of the CEO from personal liability.
10. Decision on guidelines for remuneration to senior executives.
11. Determination of the number of members of the Board of Directors and deputies.
12. Determination of the fees to be paid to the Board of Directors and auditors.
13. Election of the members of the Board (including Chairman) and deputy member(s) of the Board.
14. Election of auditor.
15. Resolution on the authorization to the Board of Directors to resolve on new issues of Series B shares.
16. Close of the Annual General Meeting.

PROPOSED DECISIONS

Election of a Chairman of the Meeting (item 2)

The Board proposes that Erik Hedlund be appointed Chairman of the Meeting.

Disposition of earnings (item 9 b)

As the company is currently in a phase of rapid expansion that requires access to capital, the Board and CEO propose that no dividend be paid to the company's shareholders. The accumulated profit of SEK 29,461,000 is proposed to be brought forward and balanced in the new accounts.

Guidelines for remuneration to senior executives (item 10)

The Board proposes the Meeting to adopt the following guidelines for remuneration to senior executives to apply for the period until the close of the Annual General Meeting of 2015.

Salary, etc.
The CEO shall receive a fixed salary and a variable remuneration. The variable remuneration shall amount to 2.0 per cent of the group's earnings before tax, though not more than six months' salary. In addition, the CEO may have other benefits of a common nature, such as a company car.

The CEO's salary shall be reviewed annually. This shall take place through negotiations between the CEO and the Chairman of the Board, after which the Chairman shall present a proposal to the other Board members. The CEO shall not be present when the Board discusses and resolves on this issue.

The other senior executives are the Chief Financial Officer (CFO), Director of Research, Director of Development, Chief Technology Officer (CTO), Director of Sales and Marketing, Director of Sales for the Asia & Pacific region, Director of Service and General Counsel.

The Director of Sales and Marketing shall receive a fixed salary and a variable remuneration. The variable remuneration shall amount to a certain percentage of the sales of RayStation® worldwide.

The Director of Sales for the Asia & Pacific region shall receive a fixed salary and a variable remuneration. The variable remuneration shall amount to a certain percentage of the sales of RayStation® in the Asia & Pacific region.

The CFO, Director of Research, Director of Development, CTO, Director of Service and General Counsel shall receive a fixed salary but no variable remuneration.

The salaries of the other senior executives shall also be reviewed annually. This shall take place in negotiations between the CEO and each individual.

Incentive programs
There are no incentive programs intended specifically for senior executives and none is proposed.

However, the senior executives, except the CEO, may participate together with the other employees in such option programs and profit-sharing programs as the company may apply.

Pensions
All pension undertakings are defined-contribution plans. The retirement age for the CEO and the other senior executives is 65 years and the pension premiums correspond to the Swedish ITP plan.

Period of notice
If the CEO terminates his employment, his period of notice is six months, and if the company terminates the CEO's employment, the period of notice is twelve months. In both cases, the CEO is entitled to salary during the period of notice. In respect of the other senior executives there is a mutual period of notice of three months during which salary shall be paid.

Severance pay
Neither the CEO nor the other senior executives shall be entitled to any severance pay, in a formal sense, should their employment cease. However, as described above, the CEO and the other senior executives shall be entitled to salary during the period of notice.

Deviation
The Board proposes that the Board be entitled to deviate from the above guidelines if there are special reasons for such deviations.

Number of members of the Board of Directors and deputies (item 11)

Shareholders representing appr. seventy percent (70%) of the total number of votes in the company propose that the number of Board members continue to be four (4), with no deputies.

Fees (item 12)

Shareholders representing appr. seventy percent (70%) of the total number of votes in the company propose:

that  remuneration to Board members who do not receive a salary from any group company, amount to a total of SEK 760,000 for the period extending to the close of the next Annual General Meeting, of which SEK 440,000 to be paid to the Chairman and SEK 160,000 to each of the Board members elected by the Annual General Meeting, who do not receive a salary from any group company.

that  the auditors' fees shall be paid in accordance with current approved invoicing.

Board of Directors, etc. (item 13)

Shareholders representing appr. seventy percent (70%) of the total number of votes in the company propose:

thatCarl Filip Bergendal, Erik Hedlund, Johan Löf and Hans Wigzell be re-elected as Board members in the company; and

that  Erik Hedlund be re-elected as Chairman of the Board.

Election of auditor (item 14)

The Board of Directors proposes that the auditing firm Ernst & Young be appointed as auditors, with the authorized public accountant Per Hedström as auditor in charge.

Resolution on the authorization to the Board of Directors to resolve on new issues of Series B shares (item 15)

The Board of Directors proposes that the Meeting authorize the Board of Directors to, on one or several occasions up until the next Annual General Meeting, resolve on new issues of Series B shares. The number of shares to be issued by virtue of the authorization shall not exceed ten per cent (10%) of the registered share capital per the date of this invitation, amounting to SEK 17,141,386.50. New share issues may be made with our without deviation from the shareholders' pre-emption right in accordance with Chapter 13, § 1, item 2 c of the Swedish Companies Act and with or without terms of issue in kind or set-off or other terms as stated in Chapter 13, § 5, first paragraph, item 6 of the Swedish Companies Act.

The purpose of the authorization is to increase the company's financial flexibility. In the event of deviation from the shareholders' pre-emption right, the subscription price shall be on market terms. Other terms may be resolved by the Board of Directors.

A valid resolution requires that the proposal be supported by shareholders representing at least two-thirds of both votes cast and shares represented at the Meeting.

Deviation from the guidelines for remuneration to senior executives adopted by the Annual General Meeting of 2013
During 2013, the Board has deviated from the guidelines for remuneration to senior executives and resolved upon a sales-related bonus to the Director of Sales and Marketing, which for 2013 amounted to SEK 156,000. The reason for the deviation is that it has been considered to be in line with market practice that a director of sales and marketing receives a sales-related variable remuneration.

Number of shares and votes and information on holding of own shares
The total number of shares in the company on the date of this invitation is 34,282,773, of which 11,324,391 are Series A shares and 22,958,382 are Series B shares, which means that there are a total of 136,202,292 votes in the company. The company holds no own shares.

Availability of documents and other issues
The Annual Report, the Auditor's Report in accordance with Chapter 8, § 54 of the Swedish Companies Act and the Board's complete proposal in accordance with the above will be held available at the company's office and on the company's website no later than from and including 6 May, 2014 and will be sent to those shareholders who have provided notice that they wish to receive such information from the company.

For the abovementioned decisions, the support of shareholders representing more than half of the votes cast is necessary, except in relation to item 15 for which a qualified majority is necessary, as specified in item 15 above.

The right of the shareholders to request information
The shareholders have the right at the Annual General Meeting to request that the Board of Directors and the CEO provide information about facts that can affect the assessment of an item on the agenda and facts that can affect the assessment of the economic situation of the company. Such information shall be provided if it can be done without substantial harm to the company. The obligation to inform also applies in respect of the company's relationship to other group companies, the consolidated financial statements and facts according to the above in respect of subsidiaries.

Stockholm, April 2014

Board of Directors

Download

RaySearch has established a German subsidiary, RaySearch Germany GmbH. The new subsidiary is fully responsible for the marketing, sales and service of RaySearch's proprietary treatment planning system RayStation® in Germany, Austria and the German-speaking parts of Switzerland. It will serve new as well as existing customers such as DKFZ and WPE in Germany and MedAustron in Austria.

The German subsidiary is led by Mr. Radu Pintea. Mr. Pintea is a trained medical physicist and brings over 20 years' experience from the radiation therapy industry and has held senior sales positions primarily in treatment planning but also in medical equipment and accessories for radiotherapy.

"I am very happy to join RaySearch in this exciting phase. RayStation® is clearly the leading treatment planning system on the market with unique features such as multi-criteria optimization and full support for adaptive therapy and proton therapy. I am off to a flying start and look forward to working with new and existing customers in the region. We will participate as an exhibitor at all the important trade shows in 2014 starting with DEGRO in Düsseldorf", says Radu Pintea, Business Director of RaySearch Germany GmbH.

Johan Löf, CEO of RaySearch, comments: "We have been active in Germany for almost five years since WPE in Essen became the very first RayStation® customer in 2009. Over the years we have supported the German-speaking market from Stockholm. As we now see an increasing demand from the region it is time to increase our presence and I am very happy to welcome Radu Pintea to RaySearch. With his extensive experience he will be instrumental to expand and support our growing customer base in the region."

About RayStation®
RayStation® integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch's products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched through partners and RaySearch's software is used at 2,500 clinics in more than 65 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Radu Pintea, Business Director, RaySearch Germany GmbH
Telephone: [phone]
[e-mail]

Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: [phone]
[e-mail]

Download

In May 2011, the US company Prowess filed a lawsuit against RaySearch at a court in Baltimore, Maryland, USA. Prowess claimed that RaySearch infringed on a US patent to which Prowess holds an exclusive license. RaySearch believed that there was no infringement and, in addition, that the patent should be invalidated since there was prior art in numerous older publications describing the same methods. RaySearch has now entered into a settlement agreement with Prowess. Under this agreement RaySearch will pay Prowess a fixed amount spread out over three years and Prowess will drop the lawsuit. Further details of the agreement are confidential.

Even though the settlement takes place in 2014 it will affect the accounts for 2013. The final financial statements in the 2013 Annual report will therefore deviate from the financial statements that were presented in the 2013 Year-end report on February 13, 2014. Adjusted for the settlement, RaySearch made an operating loss of SEK 25.7 M in 2013 instead of an operating profit of SEK 8.8 M as posted in the 2013 Year-end report. The net loss adjusted for the settlement amounts to SEK 20.8 M instead of a net profit of SEK 6.1 M as posted in the Year-end report. The full financial statements for 2013 will be available in the 2013 Annual report that is scheduled to be published in the end of April.

"The cost of running this case all the way to trial and through a potential appeal process would have been very high. Therefore it makes sense for us to take the full settlement cost now so that we can put this behind us once and for all and focus all our energy on the continued expansion of our business. I would also like to stress that RaySearch's underlying business is doing well. Excluding costs for legal fees and the settlement we made an operating profit of SEK 31.6 M in 2013", says Johan Löf, CEO of RaySearch."

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch's products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched through partners and RaySearch's software is used at over 2,300 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: [phone]
[e-mail]

Download

RaySearch Laboratories AB has entered into an exclusive distribution agreement with AlphaXRT (formerly CMS Alphatech) based in Sydney, Australia and Auckland, New Zealand. The agreement means that AlphaXRT will be fully responsible for marketing, sales and service of RaySearch's proprietary treatment planning system RayStation® in Australia and New Zealand from April 1, 2014.

Australasia is a well-established, world renowned and growing radiation therapy market. AlphaXRT is a leading distributor of software and equipment used in the treatment of cancer and represents a wide range of respected international suppliers. The company was founded in 1990 and the dedicated sales and support team at AlphaXRT are highly experienced in the field of radiation therapy treatment planning systems and serve all radiation therapy centres in Australia and New Zealand.

"AlphaXRT is delighted to be representing RaySearch Laboratories in the treatment planning market in Australasia. RaySearch have a longstanding reputation in treatment planning solutions and RayStation® is the leading independent treatment planning system available. We look forward to working with RaySearch to promote RayStation® to our customers in the region", says Richard Neale, Managing Director of AlphaXRT.

"AlphaXRT is a leading distributor of advanced radiation therapy equipment with a long track record, so we are of course delighted that they have elected to partner with RaySearch. We will now work closely together with AlphaXRT's experienced experts to satisfy the needs of existing and future RayStation® customers and I am fully convinced that this collaboration will be highly fruitful for both companies", says Johan Löf, CEO of RaySearch.

About RayStation®
RayStation® integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch's products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched through partners and RaySearch's software is used at over 2,300 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: [phone]
[e-mail]

Download

RaySearch Laboratories AB (publ.) has been awarded a contract to supply its RayStation® treatment planning system (TPS) to Tayside Cancer Centre, Ninewells Hospital & Medical School in Dundee, UK. Ninewells will be the first clinical installation of RayStation® in the United Kingdom.

Ninewells Hospital & Medical School is one of the largest teaching hospitals in Europe. It has a comprehensive regional cancer centre serving the Tayside region of Scotland. The centre offers all forms of cancer therapy and treats approximately 1400 new cancer patients annually. The radiotherapy department at Ninewells will replace its current TPS with RayStation®, as its treatment planning system for conventional 3D-CRT treatments, as well as more advanced treatments, such as IMRT and VMAT.

The order includes sophisticated solutions, such as multi-criteria optimization, enabling a more efficient treatment planning process. Multi-criteria optimization is a highly intuitive tool that lets the clinician evaluate the impact of changing different treatment priorities in real-time, which has a large potential to speed up the time-consuming plan optimization process. The radiotherapy department at Ninewells Hospital will also implement dose tracking and adaptive planning using the dedicated tools available in RayStation, as well as investigating biological optimization and evaluation.

"NHS Tayside made the decision to purchase RayStation® following a comprehensive NHS Scotland procurement and evaluation process. The process took into consideration TPS generic specifications, site specific requirements by Tayside Cancer Centre and the benefits the system will bring to the centre over and above the competing systems. We look forward to working with the RaySearch team to produce the best possible treatment plans for patients", says Salam Souliman, Head of RT Physics at Ninewells Hospital.

"The UK is a highly important market for us. We established our UK sales and service office in the second half of 2013 and this has already resulted in the first customer order. Ninewells is an excellent clinic and we are of course thrilled that they have now become our first UK customer", says Johan Löf CEO of RaySearch.

About RayStation®
RayStation® integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch's products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched through partners and RaySearch's software is used at over 2,300 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ.)
Telephone: [phone]
[e-mail]

Download